FORM 10-Q
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
[X] Quarterly report pursuant to section 13 or 15(d) of the Securities Exchange
Act of 1934
For the quarterly period ended SEPTEMBER 30, 2001 or
------------------
[_] Transition report pursuant to section 13 or 15(d) of the Securities
Exchange Act of 1934
For the transition period from ______ to ______
1-9731
(Commission file No.)
ARRHYTHMIA RESEARCH TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 72-0925679
(State or other jurisdiction of (I.R.S. employer identification no.)
incorporation or organization)
25 SAWYER PASSWAY
FITCHBURG, MASSACHUSETTS 01420
(Address of principal executive office and zip code)
(978) 345-5000
(Registrant's telephone number, including area code)
1101 SOUTH CAPITAL OF TEXAS HIGHWAY
BUILDING G - SUITE 200
AUSTIN, TEXAS 78746
(former address of principal executive office)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [X] No [_].
--- ---
As of October 31, 2001 there were 2,949,635 shares of common stock outstanding.
This report consists of 9 pages.
ARRHYTHMIA RESEARCH TECHNOLOGY, INC.
TABLE OF CONTENTS
FORM 10-Q
September 30, 2001
PART I - FINANCIAL INFORMATION.............................................3
Item 1. Financial Statements
CONSOLIDATED BALANCE SHEETS..............................................3
CONSOLIDATED STATEMENTS OF OPERATIONS....................................4
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY...............5
CONSOLIDATED STATEMENTS OF CASH FLOWS....................................6
SUPPLEMENTAL NOTES TO CONSOLIDATED FINANCIAL STATEMENTS..................7
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations...............................................7
PART II - OTHER INFORMATION................................................9
Item 1. Legal Proceedings...............................................9
Item 2. Changes in Securities...........................................9
Item 3. Defaults Upon Senior Securities.................................9
Item 4. Submission of Matters to a Vote of Security Holders.............9
Item 5. Other Information...............................................9
Item 6. Exhibits and Reports on Form 8-K................................9
SIGNATURES...............................................................9
2
ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS
(Unaudited)
September 30, December 31,
2001 2000
--------------- ---------------
ASSETS
Current assets:
Cash and cash equivalents.................................................................... $ 2,272,883 $ 1,999,292
Trade and other accounts receivable, net of allowance for doubtful accounts..................
of $50,000 and $52,827.................................................................... 1,063,823 1,604,141
Inventories, net............................................................................. 922,130 860,161
Deposits, prepaid expenses and other current assets.......................................... 38,652 62,728
Income tax recoverable....................................................................... - 100,000
--------------- --------------
Total current assets........................................................................ 4,297,488 4,626,322
Property and equipment, net of accumulated depreciation of $4,469,813 and $4,028,956.......... 3,166,230 3,310,958
Goodwill, net of accumulated amortization of $1,113,910 and $1,016,493........................ 1,359,416 1,456,833
Other intangibles, net of accumulated amortization of $576,667 and $558,419................... 29,782 48,030
Deferred income taxes, net.................................................................... 424,923 444,923
Other assets.................................................................................. 40,611 31,518
--------------- --------------
Total assets................................................................................ $ 9,318,450 $ 9,918,584
=============== ==============
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Current portion of capital lease obligations................................................. $ 10,230 $ 23,882
Current maturities of bonds payable and other long-term debt................................. 470,003 178,279
Accounts payable............................................................................. 316,318 344,821
Accrued expenses............................................................................. 265,746 407,897
--------------- --------------
Total current liabilities................................................................... 1,062,297 954,879
Bonds payable................................................................................. - 399,490
Deferred revenue.............................................................................. - 4,621
--------------- --------------
Total liabilities........................................................................... 1,062,297 1,358,990
--------------- --------------
Shareholders' equity:
Preferred stock, $1 par value; 2,000,000 shares authorized, none issued...................... - -
Common stock, $.01 par value; 10,000,000 shares authorized;
3,758,181 and 3,729,681 issued............................................................. 37,582 37,297
Additional paid-in-capital................................................................... 9,196,611 9,166,615
Common stock held in treasury, 808,546 and 563,446 shares at cost............................ (2,205,856) (1,654,664)
Retained earnings............................................................................ 1,227,816 1,010,346
--------------- --------------
Total shareholders' equity.................................................................. 8,256,153 8,559,594
--------------- --------------
Total liabilities and shareholders' equity.................................................. $ 9,318,450 $ 9,918,584
=============== ==============
The accompanying notes are an integral part of the
consolidated financial statements.
3
ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Ended Sept. 30, Nine Months Ended Sept. 30,
---------------------------- ---------------------------
2001 2000 2001 2000
---- ---- ---- ----
Revenue.......................................................... $ 1,637,050 $ 2,108,247 $ 5,265,686 $ 7,515,164
Cost of sales.................................................... 1,180,898 1,581,090 3,670,360 4,674,320
------------ ------------ ------------ ------------
Gross profit..................................................... 456,152 527,157 1,595,326 2,840,844
------------ ------------ ------------ ------------
Selling and marketing............................................ 10,748 29,868 51,943 159,065
General and administrative....................................... 295,635 437,257 1,014,469 1,394,017
Research and development......................................... 50,078 40,953 151,046 120,287
Amortization of goodwill......................................... 32,472 32,472 97,417 97,417
------------ ------------ ------------ ------------
Total expenses................................................... 388,933 540,550 1,314,875 1,770,786
------------ ------------ ------------ ------------
Income from operations........................................... 67,219 (13,393) 280,451 1,070,058
Other income (expense):
Interest expense................................................ (18,165) (22,316) (47,274) (69,635)
Other income (expense), net..................................... 8,712 (358) 20,293 (54,917)
------------ ------------ ------------ ------------
Income before income taxes....................................... 57,766 (36,067) 253,470 945,506
Income taxes..................................................... (23,000) (58,000) 36,000 177,000
------------ ------------ ------------ ------------
Net income....................................................... $ 80,766 $ 21,933 $ 217,470 $ 768,506
============ ============ ============ ============
Net income per share - basic..................................... $ 0.03 $ 0.01 $ 0.07 $ 0.23
============ ============ ============ ============
Weighted average number of common
shares outstanding.............................................. 2,976,724 3,323,229 3,034,481 3,403,422
============ ============ ============ ============
Net income per share - dilutive.................................. $ 0.03 $ 0.01 $ 0.07 $ 0.22
============ ============ ============ ============
Dilutive average number of common
equivalent shares outstanding................................... 3,150,890 3,480,313 3,202,341 3,484,301
============ ============ ============ ============
The accompanying notes are an integral part of the
consolidated financial statements.
4
ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
(Unaudited)
Retained
Common Shares Additional Unearned Earnings
------------------------- Paid-in Treasury ESOP (Accumulated
Number Amount Capital Stock Compensation Deficit) Total
----------- -------- ------------ ----------- -------------- -------------- -----------
December 31, 1998.............. 3,679,216 $ 36,792 $ 8,909,307 $ (913,084) $ (39,277) $ (34,826) $ 7,958,912
Issuance of common stock....... 32,667 327 36,986 37,313
Treasury stock purchase of
153,891 shares............ (238,808) (238,808)
ESOP payments.................. 39,277 39,277
Net income..................... 425,045 425,045
----------- -------- ------------ ------------ --------- ---------- -----------
December 31, 1999.............. 3,711,883 37,119 8,946,293 (1,151,892) - 390,219 8,221,739
Issuance of common stock....... 17,798 178 26,322 26,500
Treasury stock purchase of
265,040 shares............ (502,772) (502,772)
Value of warrants with
bond renewal.............. 194,000 194,000
Net income..................... 620,127 620,127
----------- -------- ------------ ------------ --------- ---------- -----------
December 31, 2000.............. 3,729,681 37,297 9,166,615 (1,654,664) - 1,010,346 8,559,594
Issuance of common stock....... 28,500 285 29,996 30,281
Treasury stock purchase of
245,100 shares............ (551,192) (551,192)
Net income..................... 217,470 217,470
----------- -------- ------------ ------------ --------- ----------- -----------
September 30, 2001............. 3,758,181 $ 37,582 $ 9,196,611 $ (2,205,856) $ - $ 1,227,816 $ 8,256,153
=========== ======== ============ ============ ========= =========== ===========
The accompanying notes are an integral part of the
consolidated financial statements.
5
ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Nine Months
Ended September 30,
------------------
2001 2000
---- ----
Cash flows from operating activities:
Net income................................................................................ $ 217,470 $ 768,506
Adjustments to reconcile net income to net cash provided by operating activities:
Directors fees paid in stock............................................................. - 26,500
Depreciation............................................................................. 496,033 567,072
Amortization............................................................................. 115,665 123,936
Deferred income tax provision............................................................ 20,000 100,000
Changes in assets and liabilities:
Trade and other accounts receivable...................................................... 540,318 (240,036)
Inventories.............................................................................. (61,969) (16,921)
Deposits, prepaid expenses and other assets.............................................. 114,983 169,212
Accounts payable, accrued expenses and other liabilities................................ (192,206) (92,012)
----------- -----------
Net cash provided by operating activities.............................................. 1,250,294 1,406,257
----------- -----------
Cash flows from investing activities:
Capital expenditures, net of disposals................................................... (351,305) (175,227)
Deposits on capital equipment, acquisitions and other.................................... - 143,386
Patent and software development expenditures............................................. - (8,850)
Increase in assets for sale.............................................................. - (50,000)
----------- -----------
Net cash used in investing activities.................................................. (351,305) (90,691)
----------- -----------
Cash flows from financing activities:
Issuance of common stock................................................................. 30,281 -
Increase in bonds payable due to amortization............................................ 70,513 43,821
Principal payment on long-term debt...................................................... (175,000) (70,553)
Purchase of treasury stock............................................................... (551,192) (272,934)
---------- -----------
Net cash used in financing activities.................................................. (625,398) (299,666)
---------- -----------
Net increase (decrease) in cash and cash equivalents....................................... 273,591 1,015,900
Cash and cash equivalents at beginning of period........................................... 1,999,292 455,674
---------- -----------
Cash and cash equivalents at end of period................................................. $2,272,883 $ 1,471,574
========== ===========
The accompanying notes are an integral part of the
consolidated financial statements.
6
SUPPLEMENTAL NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The unaudited interim consolidated financial statements and related notes
have been prepared pursuant to the rules and regulations of the Securities and
Exchange Commission. Accordingly, certain information and footnote disclosures
normally included in financial statements prepared in accordance with generally
accepted accounting principles have been omitted pursuant to such rules and
regulations. The accompanying unaudited interim consolidated financial
statements and related notes should be read in conjunction with the consolidated
financial statements and notes thereto included in the Company's most recent
Form 10-K covering the year ended December 31, 2000.
The information furnished reflects, in the opinion of the management of
Arrhythmia Research Technology, Inc. ("ART"), all adjustments necessary for a
fair presentation of the financial results for the interim period presented.
Interim results are subject to year-end adjustments and audit by
independent certified public accountants.
Reclassifications:
Certain accounts in the 2000 financial statements have been reclassified to
conform with the 2001 presentation.
New Accounting Standard:
In June 2001, the Financial Accounting Standards Board finalized FASB
Statements No.141, Business Combinations (SFAS 141), and No.142, Goodwill and
Other Intangible Assets (SFAS 142). SFAS 141 requires the use of the purchase
method of accounting and prohibits the use of the pooling-of-interests method
for business combinations initiated after June 30, 2001. SFAS 142 requires,
among other things, that companies no longer amortize goodwill in fiscal years
beginning after December 15, 2001, but test goodwill for impairment at least
annually.
The Company's previous business combinations were accounted for using the
purchase method. As of September 30, 2001 the net carrying amount of goodwill is
$1,359,416. Amortization expense during the nine month period ended September
30, 2001 was $97,417. Currently the Company is assessing but has not yet
determined how the adoption of SFAS 141 and SFAS 142 will impact its financial
position and results of operations.
Inventories:
Inventories consist of the following as of:
Sept. 30, Dec. 31,
2001 2000
--------- ---------
Raw materials................................... $ 156,441 $ 123,962
Work-in-process................................. 272,395 197,254
Finished goods.................................. 493,294 538,945
--------- ---------
Total......................................... $ 922,130 $ 860,161
========= =========
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
Liquidity and Capital Resources
- -------------------------------
At September 30, 2001, the Company had working capital of $3,235,191
compared to $3,671,443 at December 31, 2000. The $436,252 decrease in working
capital resulted from $470,003 of bonds payable (maturity value of $550,000)
that became a current liability in May 2001.
The Company has a $1,000,000 line of credit with a bank that was extended
through June 2002. There were no borrowings on the line of credit at September
30, 2001 or during the first nine months of 2001.
In September 2001, the Company announced the continuation of its Stock Buy-
Back Program and its intention to purchase up to an additional 200,000 shares of
the common stock of the Company. For the nine months ended September 30, 2001,
the Company acquired 245,100 shares of its common stock at an average cost of
$2.25 per share. It is intended that the repurchased shares become treasury
stock of the Company.
Results of Operations
- ---------------------
Total revenue for the third quarter of 2001 was $1,637,050 or a decrease of
22% from the third quarter of 2000 revenue. Of the $471,197 decline in third
quarter revenue, $306,859 reflects the lower sales of snaps to a major customer
of Micron Products, Inc. (a wholly owned subsidiary of the Company) which
switched to an alternate supplier. Net income for the third quarter of 2001 was
$80,766, or $58,833 better than the third quarter of 2000. The improvement in
third quarter 2001
7
earnings compared to 2000 resulted primarily from $160,742 savings in selling,
general and administrative expenses associated with the consolidation of the
Texas office into the Massachusetts facility and the reduction of management
personnel.
Included in last year's revenues and net income for the nine months ended
September 30, 2000 was $1,000,000 of revenue and $760,000 of net income from a
one time payment by GE/Prucka to terminate a commission agreement for CardioLab
sales. Excluding the one time commission payment, year to date revenues for
2001 were $5,265,686 compared to $6,515,164 for 2000. The $1,249,478 decline in
revenue is attributed to $741,390 in lower snap sales and accelerated pre-Y2K
sales that reduced early 2001 sales. Year to date, net income for 2001 is
$217,470 compared to $8,506 for 2000 excluding the one time commission payment.
In addition to the $364,960 in savings in 2001 from the reduction of selling,
general and administrative personnel and programs, no major legal expenses have
been reported in 2001, whereas in 2000 reported $121,710 for legal costs at
Micron. The savings in selling, general and administrative expenses in 2001
more than offset the $245,518 loss of gross profit on the lower sales in 2001,
excluding the one time commission payment.
Domestic and foreign sales for the third quarter and nine months are as follows:
Third Quarter Nine Months
2001 % 2000 % 2001 % 2000 %
---------- --- ------------- --- ---------- --- ---------- ---
Foreign Sales $1,326,656 81 $ 1,456,483 69 $4,355,652 83 $4,533,222 61
Domestic Sales 310,394 19 651,764 31 910,034 17 1,981,942 26
Domestic Commission -- -- -- -- -- -- 1,000,000 13
---------- --- ------------- --- ---------- --- ---------- ---
Total $1,637,050 100 $ 2,108,247 100 $5,265,686 100 $7,515,164 100
========== === ============= === ========== === =========== ===
Foreign sales continue to increase in proportion to the Company's total
sales as two major Micron customers have consolidated the majority of their
production of ECG electrodes into Canadian plants.
Cost of sales was 72% of revenue in the third quarter of 2001 compared to
75% for the same period in 2000. Cost of sales was 70% for the nine months of
2001 compared to 72% for the same period in 2000, excluding the one time
commission payment. The lower costs in 2001 reflect the lower sales volume of
snaps for which Micron acts as a distributor that have a higher cost than its
own ECG silver plated sensors.
Selling and marketing expenses are $19,120 and $107,122 below the prior
year for the third quarter and the nine months then ended, respectively. Selling
and marketing expenses have been lowered during the upgrading of ART's SAECG
products as discussed below.
Research and development expenses are $9,125 and $30,759 over the prior
year for the third quarter and the nine months then ended, respectively. The
additional funds were spent incorporating two signal averaging programs into a
single software package and evaluating alternative acquisition devices used in
conjunction with the Company's SAECG applications.
General and administrative expenses were lower in the third quarter of 2001
by $141,622 and for the nine months of 2001 by $379,548 as compared to similar
periods in 2000. In the first half of 2000, $121,710 of legal expenses were
incurred at Micron that did not repeat in 2001. The remainder of the savings are
primarily attributed to the lower management personnel and severance costs from
that which were reported in 2000.
Income taxes for the third quarters of 2001 and 2000 were both tax credits
of $23,000 and $58,000, respectively. The tax credits arise due to the
recognition of deferred Federal income tax deductions that are estimated to be
used in 2001 and subsequent years. The Company has available approximately
$1,200,000 of deferred Federal tax credits that can be utilized to offset
Federal taxes payable to the extent the Company has taxable income. Income taxes
for the nine months ended 2001 and 2000 were 14% and 19%, respectively.
Safe Harbor Under the Private Securities Litigation Reform Act of 1995.
- ----------------------------------------------------------------------
Any forward looking statements made herein are based on current
expectations of the Company that involves a number of risks and uncertainties
and should not be considered as guarantees of future performance. These
statements are made under the Safe Harbor Provisions of the Private Securities
Litigation Reform Act of 1995. The factors that could cause actual results to
differ materially include: interruptions or cancellation of existing contracts,
impact of competitive products and pricing,
8
product demand and market acceptance risks, the presence of competitors with
greater financial resources than the Company, product development and
commercialization risks and an inability to arrange additional debt or equity
financing.
PART II - OTHER INFORMATION
Item 1. Legal Proceedings - none
Item 2. Changes in Securities - none
Item 3. Defaults Upon Senior Securities - none
Item 4. Submission of Matters to a Vote of Security Holders - none
Item 5. Other Information - none
Item 6. Exhibits and Reports on Form 8-K - none
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Arrhythmia Research Technology, Inc.
------------------------------------
/s/ E.P. Marinos
---------------------
Chairman of the Board
/s/ Richard A Campbell
-------------------------
Vice President of Finance
November 13, 2001
9